<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267030</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-GRASPALL 2016</org_study_id>
    <secondary_id>2016-004451-70</secondary_id>
    <nct_id>NCT03267030</nct_id>
  </id_info>
  <brief_title>Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase</brief_title>
  <official_title>Single-Arm PharmacoKinetic/PharmacoDynamic and Safety Study of Eryaspase (GRASPA®) for Patients With Hypersensitivity to PEG-Asparaginase, Diagnosed With Ph(-) Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birgitte Klug Albertsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ERYtech Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pegylated-asparaginase (PEG-ASP) is an important part of the treatment of childhood acute
      lymphoblastic leukaemia (ALL). Unfortunately 13% of patients develops allergy and further
      treatment is impossible. Furthermore, 6% of patients have developed antibodies (silent
      inactivation) and have no effect of the PEG-ASP treatment. Truncated asparaginase therapy is
      associated with inferior event-free survival outcomes, in particular relapse in central
      nervous system (CNS).

      Eryaspase is a new formulation of asparaginase encapsulated in erythrocytes. The erythrocyte
      membrane protects asparaginase against fast degradation and elimination processes. The
      encapsulation eliminates the direct somatic contact, and it is hypothesized that this
      provides the potential to prolong the activity of the enzyme and reduce toxicities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Enzyme activity (IU/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>T1/2 (half-life time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Vss (Distribution Volume at steady state)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Mean Residence Time (MRT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic profile</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma concentrations of amino acids: asparagine, aspartate, glutamine, glutamate
o Concentrations of amino acids in the cerebrospinal fluid (CSF): (asparagine, aspartate, glutamine, glutamate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>Titers of anti-asparaginase antibodies and neutralizing antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypersensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>allergic reactions (any grade) and silent inactivation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interactions with maintenance therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of levels of maintenance metabolites from the maintenance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>GRASPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRASPA</intervention_name>
    <description>Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).</description>
    <arm_group_label>GRASPA</arm_group_label>
    <other_name>Eryaspase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 1-45 years at diagnosis of ALL

          2. First line non-high risk (HR) ALL patients enrolled in the treatment protocol Nordic
             Society of pediatric hematology and oncology (NOPHO) ALL 2008 including
             PEG-asparaginase regimen

          3. Documented hypersensitivity reaction to PEG-asparaginase with either:

             Clinical allergy to PEG-Asparaginase (mild/severe) OR Serum asparaginase activity
             below the lower level of quantification.

          4. Karnofsky/Lansky score ≥ 50.

          5. Ability to understand, and willingness to sign, a written informed consent document
             and to comply with the scheduled visits, treatment plans, laboratory tests, and other
             study procedures. For patients under 18 years of age, either both parents or the
             legally appointed representatives will need to provide consent.

        Exclusion Criteria:

          1. Philadelphia chromosome positive ALL.

          2. Participation in another clinical trial interfering with the study therapy with
             exception of NOPHO ALL-2008. Patients can participate in other clinical trials not
             interfering with the study drug. In case of doubt this is assessed by the PI.

          3. Uncontrolled intercurrent illness including, but not limited to, patients receiving
             combination antiretroviral therapy or patients with severe or systemic infection, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          4. Other severe acute/chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or study drug
             administration, or may interfere with the interpretation of study results, and in the
             judgment of the investigator would make the patient inappropriate for entry into this
             study.

          5. Pregnant or lactating females (serum human chorionic gonadotropin pregnancy test at
             screening). Use of a highly effective contraceptive measure in women of child-bearing
             potential and sexually active girls that are of child-bearing potential is required
             (contraceptive measures are specified in section 6.0).

          6. Inadequate organ functions, which prohibit further asparaginase administration;

               1. History of pancreatitis

               2. History of serious hemorrhage or serious thrombosis with prior asparaginase
                  therapy

               3. Severe hepatic impairment at the time of administration (bilirubin &gt;3 times ULN,
                  transaminases &gt;10 times ULN)

               4. Pre-existing known coagulopathy (e.g. haemophilia)

          7. History of grade 3 or higher transfusion reactions or any contraindication to receive
             blood transfusion. Presence of specific anti-erythrocytes antibodies (auto-antibodies
             or anti-public antibodies) preventing from getting a compatible packed Red Blood Cells
             for the patient.

          8. Patient under concomitant treatment likely to cause hemolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Klug Albertsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric and adolescent medicine, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgitte Klug Albertsen, MD, PhD</last_name>
    <phone>+4520224643</phone>
    <email>Biralber@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Line Stensig Lynggaard, MD</last_name>
    <phone>+4525112022</phone>
    <email>Line.stensig@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aahus University hospial, hematological department</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Skov Holm, MD, phD</last_name>
      <email>Mettehlm@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Line Stensig Lynggaard, MD</last_name>
      <phone>+45 25112022</phone>
      <email>Line.stensig@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Line Stensig Lynggaard, MD</last_name>
      <phone>+25112022</phone>
      <email>Line.stensig@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Birgitte Klug Albertsen, MD, phd</last_name>
      <phone>+45 20224643</phone>
      <email>biralber@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital, pediatric department</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruta Tuckuviene</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Hematological department</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Malthe Overgaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Child and Adolescent Medicine</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Frandsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University hospital, pediatric department</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Thude Callesen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallin Childrens Hospital</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Lepik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tartu University Clinics</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sirje Mikkel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital, Helsinki. University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samppa Ryhänen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tuuli Pöyhönen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Oulu</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riita Niinimäki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olli Lohi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Päivi Lähteenmäki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Children's Hospital</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goda Vaitkeviciene</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse Bergen</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Kristine Lehmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigurd Liestøl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Quist Paulsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn- och ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>cecilia Langenskiöld</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikael Behrendtz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes Universitets sjukhus</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Castor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgrens Barnsjukhus Karolinska</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arja Harila-Sari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>arn- och Ungdomscentrum Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrika Norén Nyström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset Uppsala</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalja Jackmann</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Birgitte Klug Albertsen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Hypersensitivity to PEG-asparaginase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

